GE Healthcare launches revolutionary Invenia ABUS 2.0 in the Middle East, setting new standards in breast cancer care

The Invenia ABUS 2.0 can boost breast cancer detection by 37.5 percent over mammography alone when used in addition to mammography, the only FDA-approved ultrasound supplementary breast screening technology explicitly designed to detect cancer in dense breast tissue. Its use is permitted in all countries in the region.

Dense breast tissue is one of the important breast cancer risk factors. Breast density is a measure of the amount of fatty tissue in the breast versus the amount of fibrous tissue in the breast. Cancer and dense tissue appear white on a mammogram, and looking for tumors in women with dense breasts can be like looking for a snowball in a snowstorm. As a result, cancers are often not seen–or “masked”–in mammography exams.

Proposing a solution for comprehensive breast screening, thereby increasing diagnostic performance, Invenia ABUS 2.0 provides a more relaxed patient experience and helps to detect breast cancer at the earliest possible level.

Refer the link to know more []